Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: A randomized, controlled trial

Yin, Li; Li, Guangping; Liu, Tong; Yuan, Ruyu; Zheng, Xintian; Xu, Gang; Xu, Yong; Che, Jingjin; Liu, Xiangli; Ma, Xiaojie; Li, Feixue; Liu, Enzhao; Chen, Xin; Wu, Lei; Fan, Zhichao; Ruan, Yan; He, Mei; Li, Yiding

doi:10.1016/j.ijcard.2012.01.017

Cited by 24 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, probucol inhibited NADPH oxidase activity in the aorta from cholesterol-fed rabbits [52]. Our previous studies suggested that prophylactic treatment with probucol during the periprocedural period in patients undergoing coronary intervention protects against contrast-induced acute kidney injury [53,54]. However, experimental studies regarding the possible benefits of probucol on atrial remodeling and AF prevention are lacking.…”

Section: Probucolmentioning

confidence: 99%

Antioxidant Therapies in the Prevention and Treatment of Atrial Fibrillation

Liu¹,

Korantzopoulos²,

Li³

2013

Atrial Fibrillation - Mechanisms and Treatment

Self Cite

View full text Add to dashboard Cite

Section: Probucolmentioning

confidence: 99%

Antioxidant Therapies in the Prevention and Treatment of Atrial Fibrillation

Liu¹,

Korantzopoulos²,

Li³

2013

Atrial Fibrillation - Mechanisms and Treatment

Self Cite

View full text Add to dashboard Cite

“…

Contrast induced nephropathy (CIN) is an important complication following coronary angiography with or without coronary intervention, and has been associated with significant morbidity and mortality [1]. CIN has become the third leading cause of hospital acquired acute renal failure [2].

…”

mentioning

confidence: 99%

Role of red blood cell distribution width in predicting contrast induced nephropathy in patients with stable angina pectoris undergoing percutaneous coronary intervention

Zhao

Gao

2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…In a recent study that showed the superior efficacy of probucol plus telmisartan to that of telmisartan alone in terms of proteinuria extent, the dosage of probucol was 1000 mg/d (500 mg twice daily) for the first 24 weeks and then 500 mg/d (250 mg twice daily) for an additional 24 weeks. 12 The protective effect of probucol in contrast-induced acute kidney injury has also been reported [15][16][17] presumably because of the antioxidant effect of probucol. The dosage of probucol in these studies, 1000 mg orally before the procedure and then 500 mg twice daily for 3 days, was much higher than that of the current study.…”

Section: Discussionmentioning

confidence: 90%

Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin–Angiotensin System Blockade

Jin

Han

et al. 2016

ATVB

View full text Add to dashboard Cite

Objective-To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Approach and Results-This was a 16-week, phase II, randomized, placebo-controlled, parallel-group study in type 2 diabetes mellitus patients with a urinary albumin/creatinine ratio of ≥300 mg/g using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, conducted in 17 tertiary referral hospitals. Eligible patients were randomized to probucol 250 mg/d (n=44), probucol 500 mg/d (n=41), and placebo (n=41) groups in a ratio of 1:1:1 after block randomization procedures, keeping the treatment assignment blinded to the investigators, patients, and study assistants. The primary end point was change in the geometric mean of urinary albumin/creatinine ratio from baseline to week 16 (ClinicalTrials.gov identifier NCT01726816). The study was started on November 8, 2012, and completed on March 24, 2014. The least squares mean change±SE from baseline in urinary albumin/creatinine ratio at week 16 was −7.2±639.5 mg/g in the probucol 250 mg/d group (n=43; P=0.2077 versus placebo group), 9.3±587.4 mg/g in the probucol 500 mg/d group (n=40; P=0.1975 versus placebo group), and 259.0±969.1 mg/g in the placebo group (n=41). Although the majority of subjects were on statins, probucol treatment significantly lowered total cholesterol and low-density lipoprotein cholesterol levels. QT prolongation occurred in one and two subjects in control and probucol 250 mg/d groups, respectively. Conclusions-Four

show abstract

Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: A randomized, controlled trial

Cited by 24 publications

References 16 publications

Antioxidant Therapies in the Prevention and Treatment of Atrial Fibrillation

Antioxidant Therapies in the Prevention and Treatment of Atrial Fibrillation

Role of red blood cell distribution width in predicting contrast induced nephropathy in patients with stable angina pectoris undergoing percutaneous coronary intervention

Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin–Angiotensin System Blockade

Contact Info

Product

Resources

About